AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

Tom Nolan reviews this week’s research Exercise for 30 minutes three times a week on an exercise bike for a month; then make the sessions an hour long and add resistance training with two sets of ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

DelveInsight's Heart failure with Reduced Ejection Fraction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, ...

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...